A 57-year-old woman is brought to the emergency department because of crampy abdominal pain and foul-smelling, watery diarrhea. One week ago, she underwent treatment of cellulitis with clindamycin. She has developed shortness of breath and urticaria after treatment with vancomycin in the past. Her temperature is 38.4°C (101.1°F). Abdominal examination shows mild tenderness in the left lower quadrant. Her leukocyte count is 12,800/mm3. An enzyme immunoassay is positive for glutamate dehydrogenase antigen and toxins A and B. Which of the following is the mechanism of action of the most appropriate pharmacotherapy for this patient's condition?

Inhibition of cell wall peptidoglycan formation

Blocking of protein synthesis at 50S ribosomal subunit

Inhibition of RNA polymerase sigma subunit

Inhibition of bacterial topoisomerases II and IV

Generation of toxic free radical metabolites

A 37-year-old woman with a history of anorectal abscesses complains of pain in the perianal region. Physical examination reveals mild swelling, tenderness, and erythema of the perianal skin. She is prescribed oral ampicillin and asked to return for follow-up. Two days later, the patient presents with a high-grade fever, syncope, and increased swelling. Which of the following would be the most common mechanism of resistance leading to the failure of antibiotic therapy in this patient?

Production of beta-lactamase enzyme

Intrinsic absence of a target site for the drug

Use of an altered metabolic pathway

Altered structural target for the drug

A 68-year-old man comes to the physician because of headache, fatigue, and nonproductive cough for 1 week. He appears pale. Pulmonary examination shows no abnormalities. Laboratory studies show a hemoglobin concentration of 9.5 g/dL and an elevated serum lactate dehydrogenase concentration. A peripheral blood smear shows normal red blood cells that are clumped together. Results of cold agglutinin titer testing show a 4-fold elevation above normal. An x-ray of the chest shows diffuse, patchy infiltrates bilaterally. Treatment is begun with an antibiotic that is also used to promote gut motility. Which of the following is the primary mechanism of action of this drug?

Inhibition of peptide translocation at the 50S ribosomal subunit

Inhibition of bacterial RNA polymerase

Inhibition of folic acid synthesis

Free radical creation within bacterial cells

Inhibition of transpeptidase cross-linking at the cell wall

You are treating a neonate with meningitis using ampicillin and a second antibiotic, X, that is known to cause ototoxicity. What is the mechanism of antibiotic X?

It binds the 30S ribosomal subunit and inhibits formation of the initiation complex

It binds the 50S ribosomal subunit and inhibits formation of the initiation complex

It binds the 30S ribosomal subunit and reversibly inhibits translocation

It binds the 50S ribosomal subunit and inhibits peptidyltransferase

It binds the 50S ribosomal subunit and reversibly inhibits translocation

A 26-year-old patient presents to your office with rhinorrhea that you believe to be viral in origin. He respectfully requests treatment with antibiotics, and he demonstrates an understanding of the risks, benefits, and alternatives to treatment. His mental status is intact, and you believe him to have full decision-making capacity. Which of the following is the best course of action?

Refer the patient to an infectious disease specialist

A 62-year-old man is brought to the emergency department from a senior-care facility after he was found with a decreased level of consciousness and fever. His personal history is relevant for colorectal cancer that was managed with surgical excision of the tumor. Upon admission, he is found to have a blood pressure of 130/80 mm Hg, a pulse of 102/min, a respiratory rate of 20/min, and a body temperature 38.8°C (101.8°F). There is no rash on physical examination; he is found to have neck rigidity, confusion, and photophobia. There are no focal neurological deficits. A head CT is normal without mass or hydrocephalus. A lumbar puncture was performed and cerebrospinal fluid (CSF) is sent to analysis while ceftriaxone and vancomycin are started. Which of the following additional antimicrobials should be added in the management of this patient?

Trimethoprim-sulfamethoxazole (TMP-SMX)

New antimicrobial development for USMLE Step 1: High-Yield Pharmacology Lessons

Resistance Mechanisms - The Enemy's Playbook

The evolution of drug resistance is a primary driver for new antimicrobial development. The most challenging pathogens are often the ESKAPE group, notorious for nosocomial infections and multidrug resistance.

📌 ESKAPE: Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter spp.
Core Defense Mechanisms:

Biofilms: Structured communities encased in a self-produced matrix, acting as a physical barrier to antibiotics and immune cells, often on medical devices.

⭐ Carbapenem-resistant Enterobacteriaceae (CRE) are a major public health threat, often carrying resistance genes like NDM-1 on mobile plasmids that can be transferred to other bacteria.

Novel Strategies - Hitting Them Where It's New

Novel Targets & Pathways
- Virulence Factor Inhibitors: Disarm pathogens without direct killing, reducing resistance pressure. E.g., toxin-neutralizing antibodies.
- Quorum Sensing Inhibitors: Block bacterial communication to prevent biofilm formation and toxin release.
- Lipopolysaccharide (LPS) Transport Inhibitors: Disrupt the outer membrane of Gram-negative bacteria.
Non-Traditional Approaches
- Bacteriophage Therapy: Viruses that specifically infect and kill bacteria; narrow-spectrum, preserving normal flora.
- Monoclonal Antibodies (mAbs):
  
  ⭐ Bezlotoxumab is a monoclonal antibody that neutralizes Clostridioides difficile toxin B, preventing recurrence of C. diff infection but not treating the active infection itself.
- Antimicrobial Peptides (AMPs): Cationic peptides that disrupt bacterial cell membranes.
Antimicrobial Potentiators
- New β-lactamase Inhibitors: Extend the activity of β-lactam antibiotics against resistant bacteria.
  - Vaborbactam (with meropenem)
  - Relebactam (with imipenem/cilastatin)

Bacterial Quorum Sensing Mechanism

The New Arsenal - Drugs on the Block

New Drug	Mechanism	Key Spectrum Highlights
Cefiderocol	Siderophore cephalosporin; binds iron for active transport.	Carbapenem-resistant Enterobacterales (CRE), Pseudomonas, Acinetobacter.
Lefamulin	Pleuromutilin; inhibits protein synthesis (50S subunit).	MRSA, S. pneumoniae, H. influenzae, atypicals (for CABP).
Eravacycline	Fluorocycline (tetracycline class); inhibits protein synthesis (30S subunit).	MRSA, VRE, CRE, anaerobes. Overcomes tetracycline resistance.
Delafloxacin	Anionic fluoroquinolone; inhibits DNA gyrase & topoisomerase IV.	MRSA, Pseudomonas, E. faecalis. Good for skin infections.
Omadacycline	Aminomethylcycline (tetracycline class); inhibits protein synthesis (30S).	MRSA, VRE, atypicals, community pathogens.

High‑Yield Points - ⚡ Biggest Takeaways

The new antimicrobial pipeline is critically slow, particularly for resistant Gram-negative bacteria (e.g., CRE).

Economic hurdles, including low profitability and high development costs, are major barriers to innovation.

Development focuses on multidrug-resistant (MDR) organisms and overcoming resistance mechanisms.

Key recent approvals include novel β-lactam/β-lactamase inhibitor combinations and siderophore-conjugate antibiotics.

Legislative incentives like the GAIN Act aim to stimulate development by offering market exclusivity.

Continue reading on Oncourse

CONTINUE READING — FREE

or get the app

App Store|Google Play